Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Biosensors and Bioelectronics

Volumn 92, Issue , 2017, Pages 482-488

  Wang, Scarlet Xiaoyan ^a   Acha, Desiree ^a   Shah, Ajit J ^a   Hills, Frank ^a   Roitt, Ivan ^a   Demosthenous, Andreas ^b   Bayford, Richard H ^a  

^a MIDDLESEX UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarker; Electrochemical biosensor; Impedance; Tau

Indexed keywords

ANTIBODIES; BIOMARKERS; BIOSENSORS; BODY FLUIDS; ELECTRIC IMPEDANCE; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ELECTRODES; GOLD; GOLD COMPOUNDS; NEURODEGENERATIVE DISEASES; PROTEINS; SELF ASSEMBLED MONOLAYERS;

ALZHEIMER'S DISEASE; ANTIBODY-ANTIGEN; BOVINE SERUM ALBUMINS; ELECTROCHEMICAL BIOSENSOR; GOLD ELECTRODES; LIMIT OF QUANTIFICATIONS; MICROBAND ELECTRODE; OPTIMAL ORIENTATION;

ELECTROCHEMICAL ELECTRODES;

BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; TAU PROTEIN; GOLD; IMMOBILIZED ANTIBODY;

ALZHEIMER DISEASE; ARTICLE; BIOSENSOR; CONTROLLED STUDY; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ELECTRODE; HUMAN; LIMIT OF QUANTITATION; POINT OF CARE TESTING; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; BLOOD; CHEMISTRY; DEVICES; ELECTROCHEMICAL ANALYSIS; EQUIPMENT DESIGN; GENETIC PROCEDURES; IMMUNOASSAY; LIMIT OF DETECTION; VALIDATION STUDY;

ANTIBODIES, IMMOBILIZED; BIOSENSING TECHNIQUES; ELECTROCHEMICAL TECHNIQUES; ELECTRODES; EQUIPMENT DESIGN; GOLD; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; TAU PROTEINS;

EID: 85008222762     PISSN: 09565663     EISSN: 18734235     Source Type: Journal    
DOI: 10.1016/j.bios.2016.10.077     Document Type: Article

References (37)

1. Brækhus, A., 2011. [Biomarkers of dementia]. Tidsskr. den Nor. lægeforening Tidsskr. Prakt. Med. ny række 131, 2218. doi: http//dx.doi.org/10.4061/2011/564321.
2. Bryan, T., Luo, X., Forsgren, L., Morozova-Roche, L. a, Davis, J.J., The robust electrochemical detection of a Parkinson's disease marker in whole blood sera. Chem. Sci., 3, 2012, 3468, 10.1039/c2sc21221h.
3. Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., Glodzik-Sobanska, L., De Santi, S., Zinkowski, R., Mehta, P., Pratico, D., Saint Louis, L.A., Wallin, A., Blennow, K., de Leon, M.J., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 30 (2009), 682–690, 10.1016/j.neurobiolaging.2007.08.010.
4. Caceres, A., Kosik, K.S., Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343 (1990), 461–463, 10.1038/343461a0.
5. Cook, C.N., Murray, M.E., Petrucelli, L., Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology. Nat. Med. 21 (2015), 219–220, 10.1038/nm.3809.
6. Drubin, D.G., Kirschner, M.W., Tau protein function in living cells. J. Cell Biol. 103 (1986), 2739–2746.
7. Esteves-Villanueva, J.O., Trzeciakiewicz, H., Martic, S., A protein-based electrochemical biosensor for detection of tau protein, a neurodegenerative disease biomarker. Analyst 139 (2014), 2823–2831, 10.1039/c4an00204k.
8. Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., Crowther, R.A., Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989), 519–526.
9. Hampel, H., Buerger, K., Zinkowski, R., Teipel, S.J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., Ohno, H., Vanmechelen, E., Vanderstichele, H., McCulloch, C., Moller, H.-J., Davies, P., Blennow, K., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 (2004), 95–102, 10.1001/archpsyc.61.1.95.
10. Hampel, H., Teipel, S.J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., Möller, H.-J., Blennow, K., Buerger, K., Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 9 (2004), 705–710, 10.1038/sj.mp.4001473.
11. Hanger, D.P., Betts, J.C., Loviny, T.L., Blackstock, W.P., Anderton, B.H., New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71 (1998), 2465–2476.
12. Horio, T., Hotani, H., Visualization of the dynamic instability of individual microtubules by dark-field microscopy. Nature 321 (1986), 605–607, 10.1038/321605a0.
13. Hu, Y.Y., He, S.S., Wang, X., Duan, Q.H., Grundke-Iqbal, I., Iqbal, K., Wang, J., Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 160 (2002), 1269–1278, 10.1016/S0002-9440(10)62554-0.
14. Hye, A., Riddoch-Contreras, J., Baird, A.L., Ashton, N.J., Bazenet, C., Leung, R., Westman, E., Simmons, A., Dobson, R., Sattlecker, M., Lupton, M., Lunnon, K., Keohane, A., Ward, M., Pike, I., Zucht, H.D., Pepin, D., Zheng, W., Tunnicliffe, A., Richardson, J., Gauthier, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's Dement. 44 (2014), 1–9, 10.1016/j.jalz.2014.05.1749.
15. Kassanos, P., Demosthenous, A., Bayford, R.H., 2008a. Towards an optimized design for tetrapolar affinity-based impedimetric immunosensors for lab-on-a-chip applications. In: Proceedings of the 2008 IEEE Biomedical Circuits and Systems Conference. IEEE, pp. 141–144. doi: http//dx.doi.org/10.1109/BIOCAS.2008.4696894.
16. Kassanos, P., Iles, R.K., Bayford, R.H., Demosthenous, A., Towards the development of an electrochemical biosensor for hCGbeta detection. Physiol. Meas. 29 (2008), S241–S254, 10.1088/0967-3334/29/6/S21.
17. Kosik, K.S., Alzheimer plaques and tangles: advances on both fronts. Trends Neurosci. 14 (1991), 218–219.
18. Lee, V.M., Trojanowski, J.Q., The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2 (1992), 653–656.
19. Liu, Y., Qing, H., Deng, Y., Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int. J. Mol. Sci 15 (2014), 7865–7882, 10.3390/ijms15057865.
20. Loo, F.-C., Ng, S.-P., Wu, C.-M.L., Kong, S.K., An aptasensor using DNA aptamer and white light common-path SPR spectral interferometry to detect cytochrome-c for anti-cancer drug screening. Sens. Actuators B: Chem. 198 (2014), 416–423, 10.1016/j.snb.2014.03.077.
21. Lu, Q., Wood, J.G., Functional studies of Alzheimer's disease tau protein. J. Neurosci. 13 (1993), 508–515.
22. Mandelkow, E.M., Mandelkow, E., Tau in Alzheimer's disease. Trends Cell Biol. 8 (1998), 425–427.
23. Martic, S., Rains, M.K., Kraatz, H.-B., Probing copper/tau protein interactions electrochemically. Anal. Biochem. 442 (2013), 130–137, 10.1016/j.ab.2013.07.015.
24. Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.-K., van der Flier, W.M., Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M., Tsolaki, M., Mulugeta, E., Rosén, E., Aarsland, D., Visser, P.J., Schröder, J., Marcusson, J., de Leon, M., Hampel, H., Scheltens, P., Pirttilä, T., Wallin, A., Jönhagen, M.E., Minthon, L., Winblad, B., Blennow, K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302 (2009), 385–393, 10.1001/jama.2009.1064.
25. Mehta, P.D., Pirttilä, T., Mehta, S.P., Sersen, E.A., Aisen, P.S., Wisniewski, H.M., Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57 (2000), 100–105.
26. Murray, M.E., Graff-Radford, N.R., Ross, O.A., Petersen, R.C., Duara, R., Dickson, D.W., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10 (2011), 785–796, 10.1016/S1474-4422(11)70156-9.
27. Perrin, R.J., Fagan, A.M., Holtzman, D.M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 (2009), 916–922, 10.1038/nature08538.
28. Price, J.L., Morris, J.C., Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45 (1999), 358–368.
29. Rains, M.K., Martić, S., Freeman, D., Kraatz, H.B., Electrochemical investigations into kinase-catalyzed transformations of tau protein. ACS Chem.Neurosci. 4 (2013), 1194–1203, 10.1021/cn400021d.
30. Rushworth, J.V., Ahmed, A., Grif, H.H., Pollock, N.M., Hooper, N.M., Millner, P.A., A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers. Biosens. Bioelectron. 56 (2014), 83–90, 10.1016/j.bios.2013.12.036.
31. Sharma, R., Deacon, S.E., Nowak, D., George, S.E., Szymonik, M.P., Tang, A.A., Tomlinson, D.C., Davies, A.G., McPherson, M.J., Wälti, C., Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity. Biosens. Bioelectron. 80 (2016), 607–613, 10.1016/j.bios.2016.02.028.
32. Shoji, M., Matsubara, E., Murakami, T., Manabe, Y., Abe, K., Kanai, M., Ikeda, M., Tomidokoro, Y., Shizuka, M., Watanabe, M., Amari, M., Ishiguro, K., Kawarabayashi, T., Harigaya, Y., Okamoto, K., Nishimura, T., Nakamura, Y., Takeda, M., Urakami, K., Adachi, Y., Nakashima, K., Arai, H., Sasaki, H., Kanemaru, K., Yamanouchi, H., Yoshida, Y., Ichise, K., Tanaka, K., Hamamoto, M., Yamamoto, H., Matsubayashi, T., Yoshida, H., Toji, H., Nakamura, S., Hirai, S., 2002. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol. Aging 23, 363–370.
33. Sparks, D.L., Kryscio, R.J., Sabbagh, M.N., Ziolkowski, C., Lin, Y., Sparks, L.M., Liebsack, C., Johnson-Traver, S., Tau is reduced in AD plasma and validation of employed ELISA methods. Am. J. Neurodegener. Dis. 1 (2012), 99–106.
34. Sunderland, T., Linker, G., Mirza, N., Putnam, K.T., Friedman, D.L., Kimmel, L.H., Bergeson, J., Manetti, G.J., Zimmermann, M., Tang, B., Bartko, J.J., Cohen, R.M., Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003), 2094–2103, 10.1001/jama.289.16.2094.
35. Tuantranont, A.(Ed.), 2013. Applications of Nanomaterials in Sensors and Diagnostics. Springer Series on Chemical Sensors and Biosensors, Springer-Verlag Berlin Heidelberg, chapters 1 and 3. http://dx.doi.org/10.1007/978-3-642-36025-1.
36. von Linstow Roloff, E., Platt, B., Biochemical dysfunction and memory loss: the case of Alzheimer's dementia. Cell. Mol. Life Sci. 55 (1999), 601–616.
37. Wimo, A., Jönsson, L., Bond, J., Prince, M., Winblad, B., The worldwide economic impact of dementia 2010. Alzheimers Dement. 9 (2013), 1–11, 10.1016/j.jalz.2012.11.006.